Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation

Haematologica

Volumn 97, Issue 6, 2012, Pages 874-882

  Kleemann, Patrick ^a   Distler, Eva ^a   Wagner, Eva M ^a   Thomas, Simone ^a   Klobuch, Sebastian ^a   Aue, Steffi ^b   Schnürer, Elke ^a   Schild, Hansjörg ^b   Theobald, Matthias ^a   Plachter, Bodo ^b   Tenzer, Stefan ^b   Meyer, Ralf G ^a   Herr, Wolfgang ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Allogeneic transplantation; Glycoprotein; T cells; Varicella zoster virus; Zoster vaccine

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; FAMCICLOVIR; GAMMA INTERFERON; GLYCOPROTEIN B; GLYCOPROTEIN E; IMMEDIATE EARLY PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS GLYCOPROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; ELECTROPORATION; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HERPES ZOSTER; HUMAN; HUMAN CELL; IMMUNOGENICITY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEMORY T LYMPHOCYTE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; VARICELLA ZOSTER VIRUS;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; ELECTROPORATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; MALE; PLASMIDS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TRANSFECTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIRAL ENVELOPE PROTEINS;

EID: 84862131829     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.052597     Document Type: Article

References (44)

1. Arvin AM. Varicella-Zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2000;6(3):219-30.
2. Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant. 1994;13(3):277-83.
3. Koc Y, Miller KB, Schenkein DP, Griffith J, Akhtar M, DesJardinJ, Snydmann DR. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant. 2000;6(1):44-9.
4. Ljungman P, Wilczek H, Gahrton G, Gustavsson A, Lundgren G, Lonnqvist B, et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant. 1986;1(2):185-92.
5. Ljungman P. Prophylaxis against herpesvirus infections in transplant recipients. Drugs. 2001;61(2):187-96.
6. Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35(11): 1065-9.
7. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study. Blood. 2006;107 (5):1800-5.
8. Erard V, Guthrie KA, Varley C, Heugel J, Wald A, Flowers ME, et al. One-year acyclovir prophylaxis for preventing varicellazoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood. 2007;110(8):3071-7.
9. Reusser P, Cordonnier C, Einsele H, Engelhard D, Link D, Locasciulli A, Ljungman P. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1996;17(5):813-7.
10. Villarreal EC. Current and potential therapies for the treatment of herpes-virus infections. Prog Drug Res. 2003;60:263-307.
11. Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med. 1991;325(22): 1545-50.
12. Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001;344 (13):955-60.
13. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-84.
14. LaRussa P, Steinberg S, Meurice F, Gershon A. Transmission of vaccine strain varicellazoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts. J Infect Dis. 1997;176(4): 1072-5.
15. Patel SR, Ortin M. Varicella-zoster reactivation in a patient receiving routine revaccinations after an allogeneic hemopoietic progenitors transplant. J Pediatr Hematol Oncol. 2005;27(2):106-8.
16. Herr W, Plachter B. Cytomegalovirus and varicella-zoster virus vaccines in hematopoietic stem cell transplantation. Expert Rev Vaccines. 2009;8(8):999-1021.
17. Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, Arvin AM. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002;347(1):26-34.
18. Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW, Arvin AM. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis. 1997;176(3):578-85.
19. Meyers JD, Flournoy N, Thomas ED. Cellmediated immunity to varicella-zoster virus after allogeneic marrow transplant. J Infect Dis. 1980;141(4):479-87.
20. Kato S, Yabe H, Yabe M, Kimura M, Ito M, Tsuchida F, et al. Studies on transfer of varicella-zoster-virus specific T-cell immunity from bone marrow donor to recipient. Blood. 1990;75(3):806-9.
21. Distler E, Schnurer E, Wagner E, von Auer C, Plachter B, Wehler D, et al. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation. Biol Blood Marrow Transplant. 2008;14(12):1417-24.
22. Thomas S, Herr W. Natural and adoptive Tcell immunity against herpes family viruses after allogeneic hematopoietic stem cell transplantation. Immunotherapy. 2011;3 (6):771-88.
23. Arvin AM. Humoral and cellular immunity to varicella-zoster virus: an overview. J Infect Dis. 2008;197(Suppl 2):S58-60.
24. Arvin AM. Cell-mediated immunity to varicella-zoster virus. J Infect Dis. 1992;166 (Suppl 1):S35-41.
25. Weinberg A, Levin MJ. VZV T-cell mediated immunity. Curr Top Microbiol Immunol. 2010;342:341-57.
26. Huang Z, Vafai A, Lee J, Mahalingam R, Hayward AR. Specific lysis of targets expressing varicella-zoster virus gpI or gpIV by CD4+ human T-cell clones. J Virol. 1992;66(5):2664-9.
27. Arvin AM, Sharp M, Smith S, Koropchak CM, Diaz PS, Kinchington P, et al. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J Immunol. 1991;146(1):257-64.
28. Sadzot-Delvaux C, Arvin AM, Rentier B. Varicella-zoster virus IE63, a virion component expressed during latency and acute infection, elicits humoral and cellular immunity. J Infect Dis. 1998;178(Suppl 1):S43-47.
29. Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood. 2000;96 (5):1857-64.
30. Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell. 1978;14(1):9-20.
31. Lampson LA, Levy R. Two populations of Ia-like molecules on a human B cell line. J Immunol 1980;125(1):293-9.
32. Spits H, Borst J, Giphart M, Coligan J, Terhorst C, De Vries JE. HLA-DC antigens can serve as recognition elements for human cytotoxic T lymphocytes. Eur J Immunol. 1984;14(4):299-304.
33. Watson AJ, DeMars R, Trowbridge IS, Bach FH. Detection of a novel human class II HLA antigen. Nature. 1983;304(5924):358-61.
34. Kramer-Albers EM, Bretz N, Tenzer S, Winterstein C, Mobius W, Berger H, et al. Oligodendrocytes secrete exosomes containing major myelin and stress-protective proteins: Trophic support for axons? Proteomics Clin Appl. 2007;1(11):1446-61.
35. Weinzierl AO, Rudolf D, Hillen N, Tenzer S, van Endert P, Schild H, et al. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur J Immunol. 2008;38(6):1503-10.
36. Kreiter S, Konrad T, Sester M, Huber C, Tureci O, Sahin U. Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA. Cancer Immunol Immunother. 2007;56(10):1577-87.
37. Sharp M, Terada K, Wilson A, Nader S, Kinchington PE, Ruyechan WT, et al. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J Infect Dis. 1992;165 (5):852-8.
38. Malavige GN, Jones L, Black AP, Ogg GS. Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol. 2008;152(3): 522-31.
39. Hayward AR. In vitro measurement of human T cell responses to varicella zoster virus antigen. Arch Virol Suppl. 2001;17: 143-9.
40. Diaz PS, Smith S, Hunter E, Arvin AM. T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol. 1989;142(2):636-41.
41. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197(6): 825-35.
42. Kimura H, Wang Y, Pesnicak L, Cohen JI, Hooks JJ, Straus SE, Williams RK. Recombinant varicella-zoster virus glycoproteins E and I: immunologic responses and clearance of virus in a guinea pig model of chronic uveitis. J Infect Dis. 1998; 178(2):310-7.
43. Hasan UA, Harper DR, Wren BW, Morrow WJ. Immunization with a DNA vaccine expressing a truncated form of varicella zoster virus glycoprotein E. Vaccine. 2002;20(9-10):1308-15.
44. Leroux-Roels G, Vassilev VP, Heineman T. An adjuvanted VZV subunit vaccine is well-tolerated and more immunogenic than a live varicella vaccine in adults. 48th Annual Meeting of the Infectious Diseases Society of America. Vancouver; 2010.